Tag:

Medivation

Latest Headlines

Latest Headlines

Medivation has 'best-in-class' ambitions for newly purchased PARP inhibitor

Medivation made a name for itself with Xtandi, the prostate cancer med that's now giving Johnson & Johnson's Zytiga a run for its money. Now, it wants to challenge other drugmakers in the PARP inhibitor field, too. 

Watch out, AZ: Medivation sees 'best-in-class' prospects for its new PARP inhibitor

Medivation made a name for itself with Xtandi, the prostate cancer med that's now giving Johnson & Johnson's Zytiga a run for its money. Now, it wants to challenge other drugmakers in the PARP inhibitor field, too.

Medivation snaps up BioMarin's late-stage breast cancer med in $410M-plus deal

Lots of companies are working to bulk up in the cancer field--but not BioMarin. Buckling down on rare diseases, the company is out-licensing its Phase III PARP inhibitor to Medivation for $410 million up front, with another $160 million in milestones.

UPDATED: BioMarin sells its PhIII cancer drug to Medivation for $570M

Setting its sights squarely on a future focused on rare diseases, BioMarin has opted to out-license its Phase III PARP inhibitor to Medivation for $410 million upfront with another $160 million in milestones.

Astellas, Medivation to amp up unbranded Xtandi marketing for pre-chemo use

Astellas and Medivation haven't been marketing Xtandi much for the pre-chemotherapy indication in prostate cancer it won last fall. Begun two months ago, the direct-to-consumer efforts--mostly in print--has appeared in journals such as  Patient Resourc e; it also includes some direct relationship marketing.

Medivation buys into PD-1, picking up where Teva left off

The prostate cancer experts at Medivation are getting into the hot field of checkpoint inhibitors for cancer, agreeing to pay Israel's CureTech as much as $335 million for the full rights to a promising Phase II asset.

Pre-chemo nod for Medivation's Xtandi sets up showdown with J&J's Zytiga

Johnson & Johnson's next-gen prostate cancer pill, Zytiga, has been cruising since it hit the market back in April 2011, but now, it may be vulnerable to market share losses for the first time. The FDA has approved Medivation and Astellas' rival, Xtandi, for use in prostate cancer patients before chemo, giving the pill a head-to-head shot at J&J's blockbuster.

Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer use

Astellas and Medivation today said they are asking the FDA for approval for Xtandi to be used on patients with metastatic castration-resistant prostate cancer who have not received chemotherapy.

Astellas, Medivation's cancer drug Xtandi scores new upbeat PhIII results

Medivation and Astellas Pharma unveiled final results on primary and secondary efficacy endpoints from their Phase III PREVAIL trial of Xtandi (enzalutamide), showing that the drug delayed tumor growth and prolonged the lives of patients with metastatic prostate cancer who previously have not undergone chemotherapy.

Prostate-cancer prodigy Xtandi shines as pre-chemo treatment

Xtandi has reached a key milestone: success in a Phase III trial eyeing the drug from Medivation and Astellas as a prechemo treatment for advanced prostate cancer.